<?xml version="1.0"?>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title>Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger</dc:title>
  <dc:creator>Campagne, G.</dc:creator>
  <dc:creator>Garba, A.</dc:creator>
  <dc:creator>Schuchat, A.</dc:creator>
  <dc:creator>/Boulanger, Denis</dc:creator>
  <dc:creator>Plikaytis, B.D.</dc:creator>
  <dc:creator>Ousseini, M.</dc:creator>
  <dc:creator>/Chippaux, Jean-Philippe</dc:creator>
  <dc:subject>SANTE PUBLIQUE</dc:subject>
  <dc:subject>VACCINATION</dc:subject>
  <dc:subject>NOURRISSON</dc:subject>
  <dc:subject>ANTICORPS</dc:subject>
  <dc:subject>DOSAGE</dc:subject>
  <dc:subject>EFFICACITE</dc:subject>
  <dc:subject>ANALYSE STATISTIQUE</dc:subject>
  <dc:subject>MENINGITE</dc:subject>
  <dc:description>Despite near elimination of Haemophilus influenzae b (Hib) meningitis from several industrialized countries following introduction of conjugate Hib vaccines into infant immunization schedules, Hib remains a major cause of meningitis and pneumonia in resource-poor countries. In Niger, Hib causes nearly 200 cases of meningitis per 100,000 children &lt; one year of age, and &gt; 40% of cases are fatal. We evaluated the immunogenicity of Hib polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) administered in the same syringe as diphtheria-tetanus-pertussis (DTP) vaccine among infants in Niger. Infants were randomized into group 1 (PRP-T at six, 10, and 14 weeks), group 2 (PRP-T at 10 and 14 weeks), or a control group (meningococcal A/C polysaccharide vaccine). By 14 weeks of age, all subjects in groups 1 and 2 had 0.15 or more microg/ml of anti-PRP antibody, and 82% versus 76% had 1.0 or more microg/ml of antibody (P = not significant). By nine months of age the proportion of infants with 0.15 or more and 1.0 or more microg/ml was group 1 = 97% and 76% ; group 2 = 93% and 67% ; controls = 10% and 2.6%. Four weeks after the first, second, and third doses of PRP-T, infants in group 1 showed geometric mean titers (GMTs) of 0.19, 3.97, and 6.09 microg/ml while infants in group 2 had GMTs of 2.40 and 4.41 microg/ml four weeks after the delayed first and second doses. Both PRP-T groups had significantly higher GMTs at 18 weeks and nine months of age than infants in the control group. The Hib PRP-T vaccine was immunogenic in infants in Niger. The strong response after PRP-T was initiated one month after the first DTP vaccination may reflect carrier priming. Two dose schedules of PRP-T should be given serious consideration, particularly if their reduced cost permits vaccine introduction that would be otherwise unaffordable. (R&#xE9;sum&#xE9; d'auteur)</dc:description>
  <dc:date>1998</dc:date>
  <dc:type>text</dc:type>
  <dc:identifier>https://www.documentation.ird.fr/hor/fdi:010016144</dc:identifier>
  <dc:identifier>fdi:010016144</dc:identifier>
  <dc:identifier>Campagne G., Garba A., Schuchat A., Boulanger Denis, Plikaytis B.D., Ousseini M., Chippaux Jean-Philippe. Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger. 1998, 59 (5),  837-842</dc:identifier>
  <dc:language>EN</dc:language>
  <dc:coverage>NIGER</dc:coverage>
  <dc:coverage>NIAMEY</dc:coverage>
</oai_dc:dc>
